Americium-241 and related transuranic ions (Am-241)

Americium-241 and related transuranic ions, such as Plutonium-239 and Curium-244, are radioactive heavy metals that represent significant internal contamination hazards in industrial, medical, or nuclear event scenarios (CDC, 2018). Upon entering the systemic circulation, these actinides typically exist in trivalent or tetravalent oxidation states and exhibit high affinity for biological ligands, often mimicking endogenous metals like iron (Fe3+) to bind with transferrin or mimicking calcium to deposit in the mineral matrix of the bone (NIH, 2023). The primary mode of toxicity is the emission of high-energy alpha particles, which cause severe localized ionization, leading to complex DNA damage and long-term risks of osteosarcoma and liver carcinoma (PubChem, 2024). In clinical pharmacology, these ions are the targets of decorporation therapy, which utilizes chelating agents to intercept the metals while they are still circulating in the plasma or extracellular fluid. Drugs like Pentetate calcium trisodium (Ca-DTPA) and Pentetate zinc trisodium (Zn-DTPA) are specifically indicated to bind these ions, forming stable, water-soluble complexes that are subsequently cleared by the kidneys (FDA, 2004). Effective therapeutic intervention requires rapid administration to prevent the sequestration of the radionuclides into deep tissue compartments where they become significantly harder to remove (IAEA, 2011).

Other names

Am-241Transuranic radionuclidesActinide ionsPlutonium-239Curium-244Heavy metal radionuclides

Chelation therapy involving the formation of stable, water-soluble complexes with metal ions in the extracellular fluid to facilitate renal excretion and prevent tissue deposition (FDA, 2004; IAEA, 2011).